Eli Lilly has initiated legal action against pharmacies and peptide vendors selling compounded versions of its weight-loss drug, retatrutide. This drug has gained attention as some Americans seek alternatives through medical spas and pharmacies for health benefits.
The lawsuit highlights concerns over the unauthorized distribution of retatrutide, which could impact the drug's market and availability. Eli Lilly aims to protect its intellectual property and ensure that consumers receive the drug through approved channels.
Watch for Eli Lilly's next steps in enforcing its patent rights, as this lawsuit may lead to stricter regulations on compounded drugs. Consumers should stay informed about the legal landscape affecting access to retatrutide and potential impacts on pricing and availability.